Abstract
Dual inhibitors that block both cyclooxygenase (COX) and lipoxygenase (LOX) metabolic pathways of arachidonic acid are expected to possess clinical advantages over the selective inhibitors of COX enzyme. One of the most promising compounds belonging to this category is licofelone ([2,2 -dimethyl -6-(4-chloropheny-7-phenyl-2,3-dihydro- 1H-pyrrazoline-5-yl] acetic acid). Originally discovered by Merckle GmbH and developed by EuroAllaince, licofelone (IC50 COX=0.21 μM, IC50 5-LOX=0.18μM) possesses significant analgesic, anti-inflammatory, and antiasthmatic effects at doses that cause no gastrointestinal (GI) side effects. The pharmacodynamic profile of licofelone has been assessed and compared with widely used NSAIDs in different animal models. The ED50 value of licofelone is reported to be 11.22- 27.07 mg/kg, po and 39.5-55-8 mg/kg, po against carrageenan-induced paw oedema and Randal Selitto hyperalgesic assay in rats, respectively. Licofelone showed analgesic effect (ED50 = 31.33 mg/kg) against acetic acid-induced writhing in mice. Licofelone has long duration of action and more effective than indomethacin and zileuton with ED50 values of 2.92 mg/kg, po and 36.77 mg/kg, po, in the mechanical hyperalgesia and cold allodynia testing, respectively, against rat model of incisional pain. Licofelone significantly ameliorated indomethacin-induced gastric ulceration, neutrophil adhesion in mesentery, and lipid peroxides in rat gastric mucosa. Also, licofelone reversed the altered vascular permeability, morphological changes, and prevented NSAIDs-related increase in leukotriene levels in gastric mucosa. The preclinical studies have shown that licofelone not only has convincing pharmacodynamic effect but also it is well tolerated. It is currently under clinical evaluation in osteoarthritis (OA), the most common form of arthritis. The present review describes pharmacological and clinical development of licofelone as a dual inhibitor.
Keywords: COX-2 inhibitors, 5-LOX pathway, NSAIDs-induced gastrointestinal damage, PGH synthase, Licofelone
Current Topics in Medicinal Chemistry
Title: Licofelone-A Novel Analgesic and Anti-Inflammatory Agent
Volume: 7 Issue: 3
Author(s): S. K. Kulkarni and Vijay Pal Singh
Affiliation:
Keywords: COX-2 inhibitors, 5-LOX pathway, NSAIDs-induced gastrointestinal damage, PGH synthase, Licofelone
Abstract: Dual inhibitors that block both cyclooxygenase (COX) and lipoxygenase (LOX) metabolic pathways of arachidonic acid are expected to possess clinical advantages over the selective inhibitors of COX enzyme. One of the most promising compounds belonging to this category is licofelone ([2,2 -dimethyl -6-(4-chloropheny-7-phenyl-2,3-dihydro- 1H-pyrrazoline-5-yl] acetic acid). Originally discovered by Merckle GmbH and developed by EuroAllaince, licofelone (IC50 COX=0.21 μM, IC50 5-LOX=0.18μM) possesses significant analgesic, anti-inflammatory, and antiasthmatic effects at doses that cause no gastrointestinal (GI) side effects. The pharmacodynamic profile of licofelone has been assessed and compared with widely used NSAIDs in different animal models. The ED50 value of licofelone is reported to be 11.22- 27.07 mg/kg, po and 39.5-55-8 mg/kg, po against carrageenan-induced paw oedema and Randal Selitto hyperalgesic assay in rats, respectively. Licofelone showed analgesic effect (ED50 = 31.33 mg/kg) against acetic acid-induced writhing in mice. Licofelone has long duration of action and more effective than indomethacin and zileuton with ED50 values of 2.92 mg/kg, po and 36.77 mg/kg, po, in the mechanical hyperalgesia and cold allodynia testing, respectively, against rat model of incisional pain. Licofelone significantly ameliorated indomethacin-induced gastric ulceration, neutrophil adhesion in mesentery, and lipid peroxides in rat gastric mucosa. Also, licofelone reversed the altered vascular permeability, morphological changes, and prevented NSAIDs-related increase in leukotriene levels in gastric mucosa. The preclinical studies have shown that licofelone not only has convincing pharmacodynamic effect but also it is well tolerated. It is currently under clinical evaluation in osteoarthritis (OA), the most common form of arthritis. The present review describes pharmacological and clinical development of licofelone as a dual inhibitor.
Export Options
About this article
Cite this article as:
Kulkarni K. S. and Pal Singh Vijay, Licofelone-A Novel Analgesic and Anti-Inflammatory Agent, Current Topics in Medicinal Chemistry 2007; 7 (3) . https://dx.doi.org/10.2174/156802607779941305
DOI https://dx.doi.org/10.2174/156802607779941305 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Current Pharmaceutical Design A Green and Efficient One-pot Synthesis of 1,2,3-Trisubstituted Pyrroles via Iodine-catalyzed Tandem Reaction
Letters in Organic Chemistry Difference in Blood Pressure Measurements Between Arms: Methodological and Clinical Implications
Current Pharmaceutical Design The Impact of Asymmetric Dimethylarginine (ADAMA), the Endogenous Nitric Oxide (NO) Synthase Inhibitor, to the Pathogenesis of Gastric Mucosal Damage
Current Pharmaceutical Design The Economics of Polypharmacology: Fixed Dose Combinations and Drug Cocktails
Current Medicinal Chemistry Current Pharmaceutical Design on Adhesive Based Transdermal Drug Delivery Systems
Current Pharmaceutical Design Post-stroke Depression Therapy: Where are we now?
Current Neurovascular Research Severe OSA Leading to Long Pauses in 24-h Holter ECG Reversed with CPAP
Current Cardiology Reviews Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry Role of NUCB2/nesfatin-1 in Glucose Control: Diverse Functions in Islets, Adipocytes and Brain
Current Pharmaceutical Design Intratubular Renin-Angiotensin System in Hypertension
Current Hypertension Reviews Pro-Inflammatory Gene Variants in Myocardial Infarction and Longevity: Implications for Pharmacogenomics
Current Pharmaceutical Design Syncytin and GCMa: Key Regulators in Human Placental Physiology and in Pre-Eclampsia
Current Women`s Health Reviews Integrated Quality by Design (QbD) Approach for Stability Indicating RPHPLC Method for the Estimation of Tadalafil Hydrochloride in Bulk Drug and Pharmaceutical Formulations
Current Pharmaceutical Analysis The Vascular Endothelin System in Hypertension - Recent Patents and Discoveries
Recent Patents on Cardiovascular Drug Discovery Important Aspects of Post-Prandial Antidiabetic Drug, Acarbose
Current Topics in Medicinal Chemistry From the Design to the Clinical Application of Thromboxane Modulators
Current Pharmaceutical Design Neonatal Environment and Neuroendocrine Programming of the Peripheral Respiratory Control System
Current Pediatric Reviews Significant Correlation between Cystatin C, Cerebral Infarction, and Potential Biomarker for Increased Risk of Stroke
Current Neurovascular Research Regulation of Vascular Genes by Glucose
Current Pharmaceutical Design